Geriatrics 5Ms Pocket Card for Medical and Dental Students
Click on the article title to read more.
Related Articles
Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial
Key Points. Epcoritamab, a CD3xCD20 bispecific antibody, plus GemOx yields deep, durable responses in second-line or later ASCT-ineligible R/R DLBCLHigher
NCCN Guidelines Updated to Include ctDNA-MRD Testing Recommendation for B-Cell Lymphoma
BOULDER, Colo., Jan. 10, 2025 (GLOBE NEWSWIRE) — Foresight Diagnostics, a leader in ultra-sensitive minimal residual disease (MRD) detection technology,…
NCCN Guidelines Updated to Include ctDNA-MRD Testing Recommendation for B-Cell Lymphoma
BOULDER, Colo., Jan. 10, 2025 (GLOBE NEWSWIRE) — Foresight Diagnostics, a leader in ultra-sensitive minimal residual disease (MRD) detection technology,…
NCCN Guidelines Updated to Include ctDNA-MRD Testing Recommendation for B-Cell Lymphoma
BOULDER, Colo., Jan. 10, 2025 (GLOBE NEWSWIRE) — Foresight Diagnostics, a leader in ultra-sensitive minimal residual disease (MRD) detection technology,…
The current landscape of frontline large B-cell lymphoma trials
Since the addition of rituximab to CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), major advances in first-line therapy of large B-cell
Building the future management of follicular lymphoma with T-cell–redirecting strategies
With the development of chimeric antigen receptor T-cell therapy and biologicals that engage both malignant B cells and normal T cells, the scene is set…
España, líder europeo en investigación clínica de medicamentos
Generar PDF Fecha de publicación: 09 de enero de 2025 Categoría: medicamentos de uso humano Referencia: MUH, 01/2025 La AEMPS autorizó en 2024 un total…
Siltuximab for chimeric antigen receptor T-cell therapy–related CRS and ICANS: a multicenter retrospective analysis
Key PointsIn this retrospective analysis, siltuximab effectively treated CRS and ICANS with an objective response rate of 75% and 60%, respectively.Siltuxi
Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomes
Key PointsAmong 259 patients receiving CAR T cells for lymphoma, 26% had weight loss, defined as >5% reduction in body mass index in the preceding…